This article has been updated from a previous version, which incorrectly stated that the company plans to shift its R&D resources toward prostate cancer classification and tissue healing in 2007.   
 
NEW YORK (GenomeWeb News) — Epigenomics, trying to recover from a year in which it lost a significant revenue-generating partner, has streamlined its product-development plans for its DNA-methylation-based screening products, and seeks to strike up “multiple non-exclusive partnerships,” the company said today.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.